首页> 美国卫生研究院文献>Journal of the Endocrine Society >OR21-02 Impact of Nodule Size on the Probability of Hurthle Cell Carcinoma and Other Cancers in Thyroid Nodules with Multiple Chromosomal Copy Number Alterations
【2h】

OR21-02 Impact of Nodule Size on the Probability of Hurthle Cell Carcinoma and Other Cancers in Thyroid Nodules with Multiple Chromosomal Copy Number Alterations

机译:OR21-02结节大小对雷疹细胞癌概率和其他染色体拷贝数改变的甲状腺结节概率的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fine-needle aspiration (FNA) of thyroid nodules yields indeterminate cytological diagnosis in ~20% of cases, confounding patient management. This includes Hurthle cell nodules, which typically yield Bethesda IV and III cytology. Chromosomal copy number alterations (CNA) are known to occur in thyroid tumors, particularly in Hurthle cell carcinomas (HCC) as well as in other typically follicular-patterned tumors including papillary thyroid carcinomas (PTC) and poorly differentiated thyroid carcinomas (PDTC). The aim of this study was to evaluate thyroid nodules tested positive for CNA but negative for all other genomic alterations using ThyroSeq v3 NGS assay in order to establish the probability of cancer in these nodules and find whether it is influenced by the pattern of CNA and nodule size. We evaluated 111 nodules with multiple CNA detected by ThyroSeq in FNA samples and available surgical pathology outcome. Of those, 69 (62%) nodules showed CNA changes consistent with genome near-haploidization (GNH) whereas 42 (38%) nodules had multiple chromosomal losses and gains (CLG). Nodule size ranged from 0.5-10.2 cm; cytology was Bethesda III in 54%, Bethesda IV in 43%, and Bethesda V-VI in 3% of cases, with Hurthle cells mentioned in the cytology report in 64% of cases. On surgical pathology, 38 (34%) of these nodules were malignant (including 24 HCC, 8 PTC, and 5 oncocytic PDTC) and 73 (66%) were benign (including 43 Hurthle cell and 18 follicular adenomas). No significant difference was observed in probability of malignancy between the two patterns of CNA (p=0.41). However, a significant correlation between the nodule size and probability of cancer was found (p=0.006). In specific CNA groups, correlation between cancer and nodule size remained significant for nodules with GNH pattern (P=0.0002), but not with CLG pattern (p=0.449). Specifically, cancer probability in nodules with GNH pattern and <2 cm in size was 14% (all cancers minimally-invasive), 2.0-2.9 cm was 33%, 3.0-3.9 cm was 50%, 4-4.9 cm was 67%, and ≥5 cm was 80%. Among high-risk cancers (widely-invasive or angioinvasive HCC, PDTC), all 10 tumors had the GNH pattern (p=0.01) and average nodule size of 4.9 cm (range, 2.1-8.5 cm). These findings suggest that CNA of both types are frequently found in Hurthle cell tumors, and probability of cancer in nodules with CNA and no other mutations increases with larger nodule size. This may help to refine the pre-operative assessment of cancer probability and risk of more aggressive disease and offer more tailored management to these patients.
机译:甲状腺结节的细针抽吸(FNA)产生〜20%的病例中不确定的细胞学诊断,混淆患者管理。这包括呼吸细胞结节,其通常产生贝乙醚IV和III细胞学。已知染色体拷贝数改变(CNA)发生在甲状腺肿瘤中,特别是在呼啸细胞癌(HCC)以及其他通常卵泡型瘤肿瘤中,包括乳头状甲状腺癌(PTC)和差异差异化的甲状腺癌(PDTC)。本研究的目的是评估甲状腺结节,用于CNA的阳性,但使用甲越乳膏V3 NGS测定的所有其他基因组改变的阴性,以便在这些结节中建立癌症的概率,并找到它是否受到CNA和结节的模式的影响尺寸。我们评估了111种结节,其在FNA样品中检测到多个CNA,以及可用的手术病理结果。其中69(62%)结节显示CNA变化与基因组近千倍化(GNH)一致,而42(38%)结节具有多种染色体损失和增益(CLG)。结节尺寸范围为0.5-10.2厘米;细胞学是百乙醚III,在43%的43%,贝塞斯达V-VI中,3%的病例中,细胞学报告中提到的暂缓细胞在64%的病例中提及。在外科病理学上,这些结节的38个(34%)是恶性的(包括24个HCC,8个PTC和5个生物缩损PDTC),73(66%)是良性的(包括43个泄漏细胞和18个卵泡腺瘤)。在CNA的两种模式之间的恶性肿瘤之间没有观察到显着差异(p = 0.41)。然而,发现结节尺寸与癌症概率之间的显着相关性(p = 0.006)。在特定的CNA基团中,癌症和结节尺寸之间的相关性对于具有GNH模式的结节(P = 0.0002),但不具有CLG图案(P = 0.449)。具体地,具有GNH模式的结节和<2cm的细节中的癌症概率为14%(所有癌症最小侵入性),2.0-2.9cm为33%,3.0-3.9cm为50%,4-4.9cm为67%, ≥5厘米为80%。在高风险癌症(广泛侵入性或血管侵袭性HCC,PDTC)中,所有10个肿瘤的GNH模式(P = 0.01)和平均结节尺寸为4.9cm(范围,2.1-8.5cm)。这些发现表明,两种类型的CNA经常发现在暂时的细胞肿瘤中,以及具有CNA结节中的癌症的概率,并且没有其他突变随着较大的结节尺寸而增加。这可能有助于改善对癌症概率的术前评估和更具侵略性疾病的风险,并为这些患者提供更量身定制的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号